CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-beta, TNF-alpha, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compounds ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.
Molecular Weight:
329.82
Formula:
C18H20ClN3O
Target:
Interleukin|||TGF-beta/Smad
* VAT and and shipping costs not included. Errors and price changes excepted
